Abstract:Gambogic acid (GA) is an anticancer agent in phase ‖b clinical trial in China but its mechanism of action has not been fully clarified. The present study was designed to search the possible target-related proteins of GA in cancer cells using proteomic method and establish possible network using bioinformatic analysis. Cytotoxicity and anti-migration effects of GA in MDA-MB-231 cells were checked using MTT assay, flow cytometry, wound migration assay, and chamber migration assay. Possible target-related proteins of GA at early (3 h) and late stage (24 h) of treatment were searched using a proteomic technology, two-dimensional electrophoresis (2-DE). The possible network of GA was established using bioinformatic analysis. The intracellular expression levels of vimentin, keratin 18, and calumenin were determined using Western blotting. GA inhibited cell proliferation and induced cell cycle arrest at G2/M phase and apoptosis in MDA-MB-231 cells. Additionally, GA exhibited anti-migration effects at non-toxic doses. In 2-DE analysis, totally 23 possible GA targeted proteins were found, including those with functions in cytoskeleton and transport, regulation of redox state, metabolism, ubiquitin-proteasome system, transcription and translation, protein transport and modification, and cytokine. Network analysis of these proteins suggested that cytoskeleton-related proteins might play important roles in the effects of GA. Results of Western blotting confirmed the cleavage of vimentin, increase in keratin 18, and decrease in calumenin levels in GA-treated cells. In summary, GA is a multi-target compound and its anti-cancer effects may be based on several target-related proteins such as cytoskeleton-related proteins.

Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis.

Gambogic Acid as a Candidate for Cancer Therapy: A Review

Gambogic Acid Inhibits Angiogenesis and Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2 Signaling.

Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells.

Gambogic Acid Inhibits Angiogenesis Through Suppressing Vascular Endothelial Growth Factor-Induced Tyrosine Phosphorylation of Kdr/Flk-1

Unveiling Gambogenic Acid as a Promising Antitumor Compound: A Review

Discovery of a Highly Potent and Novel Gambogic Acid Derivative As an Anticancer Drug Candidate.

Gambogic Acid Suppresses Cancer Invasion and Migration by Inhibiting TGFβ1-induced Epithelial-to-mesenchymal Transition.

Studies on Chemical Modification and Biology of a Natural Product, Gambogic Acid (III): Determination of the Essential Pharmacophore for Biological Activity

Gambogic Acid Inhibits Growth, Induces Apoptosis, And Overcomes Drug Resistance In Human Colorectal Cancer Cells

Synthesis and Antiangiogenic Activity of Novel Gambogic Acid Derivatives

Differential Apoptotic Induction of Gambogic Acid, a Novel Anticancer Natural Product, on Hepatoma Cells and Normal Hepatocytes.

Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study.

Gambogic Acid Inhibits Gastric Cancer Cell Proliferation through Necroptosis

Anti-Invasive Effect Of Gambogic Acid In Mda-Mb-231 Human Breast Carcinoma Cells

Gambogic acid as a non-competitive inhibitor of ATP-binding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATP-binding cassette transporter B1 protein degradation.

Gambogic acid impairs tumor angiogenesis by targeting YAP/STAT3 signaling axis.

Gambogenic acid inhibits proliferation of A549 cells through apoptosis-inducing and cell cycle arresting.

Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway

Proteomic and Bioinformatic Analyses of Possible Target-Related Proteins of Gambogic Acid in Human Breast Carcinoma MDA-MB-231 Cells.

Gambogic Acid Inhibits Tumor Cell Adhesion by Suppressing Integrin Β1 and Membrane Lipid Rafts-Associated Integrin Signaling Pathway.